• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

去分化软骨肉瘤的治疗经验。

Experience in the treatment of dedifferentiated chondrosarcoma.

作者信息

Mitchell A D, Ayoub K, Mangham D C, Grimer R J, Carter S R, Tillman R M

机构信息

Royal Orthopaedic Hospital Oncology, Service, Woodlands, Northfield, Birmingham, UK.

出版信息

J Bone Joint Surg Br. 2000 Jan;82(1):55-61. doi: 10.1302/0301-620x.82b1.9020.

DOI:10.1302/0301-620x.82b1.9020
PMID:10697315
Abstract

Dedifferentiated chondrosarcoma is a rare, highly malignant variant of chondrosarcoma in which a high-grade spindle-cell sarcoma coexists with a lower-grade chondroid tumour. We have reviewed our experience with this neoplasm in 22 patients, all of whom were treated using modern oncological principles of planned resection and chemotherapy. Despite this the median survival was under nine months and only 18% were alive at five years. Those patients who received chemotherapy, and in whom wide margins of excision were achieved at operation, did best. It is essential to have an accurate preoperative diagnosis in order to plan treatment which may offer a better prospect of cure.

摘要

去分化软骨肉瘤是软骨肉瘤中一种罕见的、高度恶性的变异型,其中高级别梭形细胞肉瘤与低级别软骨样肿瘤共存。我们回顾了22例该肿瘤患者的治疗经验,所有患者均采用现代肿瘤学的计划性切除和化疗原则进行治疗。尽管如此,中位生存期仍不足9个月,5年生存率仅为18%。那些接受化疗且手术切缘达到广泛切除的患者预后最佳。为了制定可能提供更好治愈前景的治疗方案,准确的术前诊断至关重要。

相似文献

1
Experience in the treatment of dedifferentiated chondrosarcoma.去分化软骨肉瘤的治疗经验。
J Bone Joint Surg Br. 2000 Jan;82(1):55-61. doi: 10.1302/0301-620x.82b1.9020.
2
Chondrosarcoma of bone: an assessment of outcome.骨软骨肉瘤:疗效评估
J Bone Joint Surg Am. 1999 Mar;81(3):326-38. doi: 10.2106/00004623-199903000-00004.
3
Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes.去分化软骨肉瘤:化疗的作用及最新疗效
J Bone Joint Surg Am. 2004 Nov;86(11):2412-8.
4
Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute.去分化骨旁骨肉瘤:里佐利研究所的经验
Cancer. 2005 Jun 1;103(11):2373-82. doi: 10.1002/cncr.21039.
5
[Cartilage tumours of the bone. Diagnosis and therapy].[骨软骨肿瘤。诊断与治疗]
Orthopade. 2006 Aug;35(8):871-81; quiz 882. doi: 10.1007/s00132-006-0991-1.
6
[Dedifferentiated chondrosarcoma. A study of 13 clinical cases and review of the literature].[去分化软骨肉瘤。13例临床病例研究及文献复习]
Rev Chir Orthop Reparatrice Appar Mot. 1994;80(8):669-80.
7
Conventional Primary Central Chondrosarcoma of the Pelvis: Prognostic Factors and Outcome of Surgical Treatment in 162 Patients.骨盆常规中央性软骨肉瘤:162 例患者手术治疗的预后因素和结果。
J Bone Joint Surg Am. 2018 Feb 21;100(4):316-325. doi: 10.2106/JBJS.17.00105.
8
Locally recurrent chondrosarcoma of the pelvis and limbs can only be controlled by wide local excision.骨盆和四肢局部复发性软骨肉瘤只能通过广泛局部切除来控制。
Bone Joint J. 2019 Mar;101-B(3):266-271. doi: 10.1302/0301-620X.101B3.BJJ-2018-0881.R1.
9
Outcome of pathologic fractures of the proximal femur in nonosteogenic primary bone sarcoma.非成骨性原发性骨肉瘤股骨近端病理性骨折的转归。
Eur J Surg Oncol. 2011 Jun;37(6):532-6. doi: 10.1016/j.ejso.2011.02.007. Epub 2011 Mar 4.
10
Can Machine-learning Techniques Be Used for 5-year Survival Prediction of Patients With Chondrosarcoma?机器学习技术可用于预测软骨肉瘤患者的 5 年生存率吗?
Clin Orthop Relat Res. 2018 Oct;476(10):2040-2048. doi: 10.1097/CORR.0000000000000433.

引用本文的文献

1
Establishment and characterization of TK-DDCS1: a novel IDH1 mutated dedifferentiated chondrosarcoma cell line.TK-DDCS1的建立与鉴定:一种新型异柠檬酸脱氢酶1(IDH1)突变的去分化软骨肉瘤细胞系
Hum Cell. 2025 Jun 3;38(4):116. doi: 10.1007/s13577-025-01235-6.
2
Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1.源自传统中央型3级软骨肉瘤的新型患者源细胞系NCC-CS1-C1的建立与鉴定
Hum Cell. 2024 Dec 8;38(1):28. doi: 10.1007/s13577-024-01152-0.
3
The clinical outcomes and prognostic factors of dedifferentiated central chondrosarcoma in extremities.
四肢去分化中心性软骨肉瘤的临床结果和预后因素。
J Orthop Surg Res. 2024 Oct 3;19(1):621. doi: 10.1186/s13018-024-05098-9.
4
A Systematic Review of Adjuvant Chemotherapy in Localized Dedifferentiated Chondrosarcoma.局限性去分化软骨肉瘤辅助化疗的系统评价
Curr Oncol. 2024 Jan 19;31(1):566-578. doi: 10.3390/curroncol31010040.
5
Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy.2级、3级和去分化软骨肉瘤:异柠檬酸脱氢酶突变型和野生型肿瘤的比较研究及其对预后和治疗的意义
Cancers (Basel). 2024 Jan 5;16(2):247. doi: 10.3390/cancers16020247.
6
Dedifferentiated Chondrosarcoma: Diagnostic Controversies and Emerging Therapeutic Targets.去分化软骨肉瘤:诊断争议与新兴治疗靶点
Curr Oncol Rep. 2023 Oct;25(10):1117-1126. doi: 10.1007/s11912-023-01441-1. Epub 2023 Aug 21.
7
Dedifferentiated Chondrosarcoma from Molecular Pathology to Current Treatment and Clinical Trials.去分化软骨肉瘤:从分子病理学到当前治疗及临床试验
Cancers (Basel). 2023 Aug 1;15(15):3924. doi: 10.3390/cancers15153924.
8
A retrospective case-control study for the comparison of 5-year survival rates: the role of adjuvant and neoadjuvant chemotherapy in craniofacial bone sarcoma in adults.一项比较5年生存率的回顾性病例对照研究:辅助化疗和新辅助化疗在成人颅面骨肉瘤中的作用。
Ther Adv Med Oncol. 2023 Feb 15;15:17588359221148023. doi: 10.1177/17588359221148023. eCollection 2023.
9
Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options.高级别软骨肉瘤的生物学特性与治疗管理:靶点与治疗选择的最新进展。
Int J Mol Sci. 2023 Jan 10;24(2):1361. doi: 10.3390/ijms24021361.
10
Case report: Treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response.病例报告:帕博利珠单抗治疗转移性去分化软骨肉瘤取得持续完全缓解。
Front Oncol. 2022 Nov 17;12:991724. doi: 10.3389/fonc.2022.991724. eCollection 2022.